1. Introduction {#sec1}
===============

Potential antimalarial drugs such as chloroquine (CQ) and hydroxychloroquine (HCQ) have been long used to prophylaxis and treatment of malaria ([@bib96]). Although, administration of CQ and HCQ have extended to several inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and against some viruses including human immunodeficiency virus (HIV), and influenza ([@bib14]; [@bib61]). The current pandemy of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a high morbidity and mortality with 17, 189, 755 confirmed cases and 670,256 deaths until July 30, 2020 ([@bib98]). Recently several studies suggested that HCQ could be an effective agent to decrease the viral load, and ameliorate clinical manifestations of patients infected with SARS-CoV-2 ([@bib12], [@bib13]; [@bib27]). Even though, clinical trial studies of HCQ in patients with SARS-CoV-2 showed inconsistent results about the effect of HCQ on decreasing patients\' infection ([@bib12], [@bib13]; [@bib27]). There is some evidence that administration of HCQ gives rise to retinopathy in some patients affected with autoimmune diseases such as RA and SLE ([@bib35]; [@bib42]). It\'s noteworthy that several risk factors including duration of use, exceeding of recommended dose (\>5 mg/kg per day (400 mg in an 80 Kg person)), and pre-existing retinal disease have been identified for ocular toxicity in patients who were under HCQ therapy. Correspondingly, there is also evidence that prolonged use of HCQ increases the risk of ocular toxicity, and high doses could lead to rapid changes in vision and consequently retinopathy development. The much higher doses of HCQ used in combat against viral infections such as SARS-CoV-2 (600 or 1000 mg daily dose) in comparison with its recommended doses for treatment of RA and SLE (200--400 mg/day) have raised the possibility of more remarkable retinopathy progression in SARS-CoV-2 patients under HCQ therapy ([@bib51]; [@bib27]; [@bib67], [@bib74]). Furthermore, growing body of evidence demonstrated that several factors including *CYP450* single nucleotide polymorphisms (SNPs), and epigenetic molecules such as non-coding RNAs (ncRNAs), DNA methylation and histone acetylation influenced the expression levels of *CYP450*, and consequently might influence HCQ metabolism. ([@bib45]; [@bib105]; [@bib95]). The major purpose of this review is to discuss the pharmacokinetic and pharmacodynamic characteristics of CQ and HCQ that may be influenced by epigenetic mechanisms including ncRNAs and *CYP2D6* SNPs, and thereby cause several side effects such as cardiotoxicity, prolonged QT interval, gastrointestinal problems (like dyspepsia and abdominal cramps), central nervous system or skin disorders, and especially retinopathy. Also, we review the advantage of personalized medicine to determining HCQ dosage regarding the unique genotype of patients for SARS-CoV-2 treatment.

2. History and pharmacokinetic characterization of hydroxychloroquine and chloroquine {#sec2}
=====================================================================================

CQ and HCQ have been long recognized as antimalarial drugs ([@bib7]). Administration of these drugs rapidly developed in management of several disorders including RA and SLE due to their rapid absorption, low cost, and immunomodulatory properties ([@bib70]). Both drugs are appropriately distributed to aqueous cellular and intercellular compartments after oral administration, and have a prolonged residence time (one month in average) ([@bib5]; [@bib76]). [Table 1](#tbl1){ref-type="table"} summarizes the pharmacokinetic of these drugs. HCQ similar to CQ is absorbed by upper intestinal tract cells, and its renal clearance is 2.5 times less than CQ (HCQ: 21% versus CQ: 51%). The apparent volumes of distribution of HCQ are 47,257 L (calculated from plasma) and 5500 L (calculated from blood), respectively which would indicate that HCQ accumulates in other compartments. CQ has an apparent volume of distribution equal to 65,000 L (calculated from plasma), and 15,000 L (calculated from blood) ([@bib17]; [@bib85]). Also, un-metabolized excretion of HCQ (62%) is approximately similar to CQ (58%) ([@bib15]; [@bib17]). Accumulating evidence revealed that HCQ similar to CQ is excreted into breast milk, and moves across the placenta to exert its pharmacokinetic effects on fetus ([@bib40]; [@bib58]). Recently, HCQ was mostly applied to treat a wide spectrum of disorders including connective tissue diseases, and autoimmune disorders in comparison with CQ due to lower toxicity, and side effects ([@bib49], [@bib50]; [@bib80]). Previous studies on animal models revealed that HCQ may be distributed in a wide spectrum of tissues including adrenal, spleen, lung, liver, kidney, heart, retina-choroid, skin, pituitary, muscle, brain, fat, and bone ([@bib53]; [@bib54]).Table 1Pharmacokinetic of hydroxychloroquine and chloroquine.Table 1Pharmacokinetic featuresHCQCQ**Absorption Locations**Upper intestinal tractUpper intestinal tract**Renal Clearance**21%51%**Plasma (V**~**D**~**)**47,257 L65,000 L**Blood (V**~**D**~**)**5500 L15,000 L**Excretion**62%58%**Breast milk Excretion**YesYes**Transport from placenta**YesYes[^1]

3. Mechanism of action of hydroxychloroquine {#sec3}
============================================

Several studies conducted on pharmacodynamic of HCQ proposed a multi-pathway model for HCQ effects ([@bib23]; [@bib36]). Obtained results showed that the major mechanism of HCQ action is modulation (elevation) of cellular pH ([@bib60]; [@bib23]). HCQ properly passes through the lysosomal membrane, and inhibits several processes including protein degradation, antigen presentation, and toll- like receptor (TLR) signalling by increasing the pH of lysosome and endosome from 4 to 6 ([@bib23]; [@bib36]). Elevated levels of pH in lysosome lead to metabolites deposition, and impediment of antigen presentation mediated by major histocompatibility complex (MHC) class II through lysosomal acidic hydrolysis blockage ([@bib23]; [@bib76]). Inhibition of antigen presenting cells including dendritic cells, macrophages, and B cells prevents the process of T cells activation mediated by MHC ([Fig. 1](#fig1){ref-type="fig"} A) ([@bib29]). Several studies reported that lysosomal enzymes blockage prolongates the degradation of macromolecules in lysosome, and thereby progressively converts them into lipofuscin ([@bib19]; [@bib82]). Lipofuscins are brown-yellow accumulated metabolites such as inclusions which appear gradually with age ([@bib84]). On the other hand, HCQ prevents from autoantigen presentation mediated by MHC II on antigen presenting cells due to obstruction of autoantigenic proteins degradation ([@bib102]). Furthermore, HCQ exerts its anti inflammatory effects via increasing the pH levels of endosome which is essential in TLR signaling in innate immunity ([@bib87]). Also, HCQ could inhibit the innate immunity by binding to TLR ligands including DNA and single strand RNA (ssRNA) which interact with TLR9 and TLR7, respectively ([@bib76]; [@bib87]). Strinkingly, several recent studies suggested that HCQ acts as an anti inflammatory agent through disruption in cyclic GMP-AMP (cGAMP) synthase (cGAS) binding with its ligand (cytosolic DNA) ([@bib2], [@bib4]). Activated cGAS by binding to cytosolic DNA leads to production and binding of cGAMP to stimulator of interferon genes (*STING*), and thereby production of several cytokines especially type I interferons ([@bib3]; [@bib106]). Recent findings revealed that palmitoyl-protein thioesterase 1 (PPT1) that is localized in lysosome, is a central target of HCQ to modulating of pH ([@bib73]). PPT1 enzyme cleaves and removes long-chain fatty acids called palmitate from proteins that are no longer required. PPT1 facilitates tumor growth via two downstream pathways including mTOR and autophagy ([@bib72]). Increasing body of evidence illustrated that HCQ potentially prevents tumor growth and inflammatory pathways (e.g RA) via inhibiting PPT1 ([Fig. 1](#fig1){ref-type="fig"}B) ([@bib16]; [@bib76]). Recently, organic anion transporter family member 1A2 (OATP1A2) was identified as a novel target of HCQ ([@bib99]). OATP1A2, is a solute carrier transporter, expressed in a wide spectrum of tissues such as brain, liver, breast, testis, lung, kidney, and in retinal pigment epithelial (RPE) cells to regulate the transport and uptake of multiple substrates especially drugs and xenobiotics ([@bib41]). Collectively, HCQ by influencing multiple pathways supresses inflammation in several inflammatory diseases, infectious diseases, cancers, and recently SARS-CoV-2 infection.Fig. 1**Mechanism of hydroxychloquine action**.A: HCQ inhibits the innate and adaptive immune system via preventing T cells antigen presentation mediated by MHC II on APC; B: hydroxychloroquine (HCQ) enters and accumulates in lysosomes and endosomes, and causes an increase of their pH. HCQ potentially inhibits tumor growth by inhibiting PPT1 (resided in lysosome) and its downstream pathways. Also, HCQ prevents the expression of pro-inflammatory cytokines by inhibiting toll-like receptors (TLR) and cyclic GMP-AMP (cGAMP) synthase (cGAS)--STING signaling; IL: interleukin; TCR: T cell receptor; RER: rough endoplasmic reticulum; IFNγ: Interferon gamma; PPT1: palmitoyl-protein thioesterase 1; APCs: antigen presenting cells; MHC II: major histocompatibility complex II.Fig. 1

4. Role of hydroxychloroquine and chloroquine in treating SARS-CoV-2 {#sec4}
====================================================================

It is becoming increasingly evident that HCQ may probably be a potential agent to combat SARS-CoV-2 ([@bib49], [@bib50]). Previously, several studies revealed the antiviral effects of HCQ against some viruses such as HIV and influenza ([@bib14]; [@bib61]). Recently, various studies demonstrated that HCQ prevents SARS-CoV-2 from cell entry via several processes ([Fig. 2](#fig2){ref-type="fig"} ). HCQ interferes with enzymes involved in glycosylation and activation of angiotensin converting enzyme (ACE) including glycosyltransferases and sugar-modifying enzymes, and consequently blocks virus-membrane fusion. Also, HCQ interferes with spike (S) protein glycosylation, and disrupts endosome-mediated virus cell fusion. Moreover, HCQ impedes S protein cleavage which is a key point for cell fusion of SARS-CoV-2 by increasing lysosomal pH levels, and inhibiting its proteases ([@bib27]; [@bib55]; [@bib93]; [@bib101]). Also, recent *in vitro* study showed that HCQ and CQ could decrease the viral replication in a concentration-dependent manner. Moreover, HCQ showed a higher safety and anti-SARS-CoV-2 efficacy relative to CQ ([@bib101]). HCQ may also prevent from SARS-CoV-2 spreading after cell entry through elevating 'endosomal and lysosomal pH, and thereby preventing from activation of inflammation cascades ([@bib78]; [@bib93]). Furthermore, pseudovirion colocalization with Niemann-Pick C1 (NPC1)-positive endolysosomes (LE/Lys) disclosed that HCQ could exert its antiviral effects through disturbance in SARS-CoV-2 replication ([@bib78]). Intriguingly, a study performed on HCQ mechanism of action illustrated that HCQ inhibits viral genome release by changing the number, size, and morphology of early endosomes or endolysosomes ([@bib49], [@bib50]; [@bib56]). Furthermore, HCQ could diminish inflammation responses through several pathways including inhibiting MHC II-mediated T cell activation, inhibiting the release of cytokines such as IL-1, IL-6, TNF-α induced by T-cell activation, blockage of TLR signaling, stimulation of interferon genes (the STING pathway) by cGAS and thereby inhibiting cytokines release including I interferon, IL-1 and TNF-α induced by TLR and STING signaling ([Fig. 1](#fig1){ref-type="fig"}A and B) ([@bib23]; [@bib76]; [@bib29]; [@bib87]; [@bib2]). Therefore, anti-inflammatory mechanism of HCQ action created this hypothesis that it might be able to halt cytokine release syndrome, and reduce consequently organ damage especially lung, induced by COVID-19. There are some reports about the remarkable association between cytokine storm especially IL-6 and clinical and pathological manifestations of patients with SARS-CoV-2, serum SARS-CoV-2 viral load (RNAaemia), and mechanical ventilation requirement ([@bib12], [@bib13]; [@bib25]; [@bib28]; [@bib49], [@bib50]). Collectively, HCQ could exert its anti-COVID-19 effects via impeding virus\' cell entry and post cell entry events such as viral replication, and inflammatory responses.Fig. 2**Hydroxychloroquine inhibits SARS-CoVs\' cell entry**.HCQ inhibits cell entry of SARS-CoV-2 via several processes including blockage of glycosylation and of activation of angiotensin converting enzyme (ACE) and spike (S) protein mediated by glycosyltransferases and sugar-modifying enzymes, preventing endosome-mediated cell fusion of SARS-CoV-2, inhibiting S protein cleavage by disrupting lysosome acidic condition, preventing inflammatory signaling activation, impeding SARS-CoV-2 replication, and preventing viral genome release by interfering with early endosomes (EEs) or endolysosomes (ELs); TMPRSS2: transmembrane protease serine protease 2; RER: rough endoplasmic reticulum.Fig. 2

5. Cytochrome P450 is a key modulator in hydroxychloroquine metabolism: implication in drug-drug interaction {#sec5}
============================================================================================================

HCQ is structurally different from CQ only by a hydroxyl group in its N-ethyl side chain ([@bib22]). CYP450 and its isoforms play a crucial role in HCQ and CQ metabolism ([@bib80]). Both of them undergo some changes especially dealkylation by CYP isomers, and become converted into active metabolites ([@bib24]; [@bib68]). Several investigations suggested that multiple CYP450 isoforms are involved in HCQ and CQ metabolism including CYP2C8, CYP3A4, CYP2D6, and CYP1A1 although the first three of them are more important relative to CYP1A1 ([Fig. 3](#fig3){ref-type="fig"} ) ([@bib44]; [@bib68]). There is some evidence that administration of HCQ could interfere with other CYP-metabolized drugs such as metoprolol ([@bib77]). Metoprolol is a beta blocker drug metabolized through CYP2D6 that is administered to prevent angina (chest pain) and manage high blood pressure. During HCQ and metoprolol combination therapy, HCQ interferes with metoprolol metabolism by competing for CYP2D6 ([@bib77]). Another drug-drug interaction that could take place is simultaneous administration of HCQ and methotrexate in management of RA. HCQ decreases the gastrointestinal absorption and bioavailability of methotrexate by modulating pH levels ([@bib6]). Concurrent administration of low dose of CQ with cyclosporine was shown to cause a better treatment in patients with RA via synergic effects with cyclosporine, although significant renal dysfunction was observed ([@bib39]). It\'s noteworthy to mention that HCQ could interfere with those drugs elevating gastric pH levels (e.g. H^+^/K^+^ ATPase pump inhibitors) including omeprazole, lansoprazole, pantoprazole, esomeprazole, and rabeprazole ([@bib59]). Therefore administration of HCQ in patients with COVID-19 that are simultaneously taking other mentioned drugs could lead to unwanted side effects.Fig. 3**Metabolism and drug-drug interactions of HCQ.** CYP450 and its isoforms mediate dealkylation of HCQ. Co-administration of HCQ or CQ with other drugs leads to different pharmacokinetic effects.Fig. 3

6. Expression levels of *CYP450* variants are influenced by epigenetic mechanisms {#sec6}
=================================================================================

NcRNAs such as miRNAs and lncRNAs affect post-transcriptionally the expression levels of several *CYP* genes, and thereby influence the metabolism, and bioavailability of CYP450-mediated drugs ([@bib30]; [@bib31]). Moreover, DNA methylation and histone acetylation could affect the CYP-metabolized drugs through modulating *CYP* expression. [Table 2](#tbl2){ref-type="table"} summarizes known epigenetic modulators of *CYP450* variants and their mechanism of action. However, more studies are needed to recognizing of other CYP modulators that could pave the way to refine HCQ dosage, and further reduce its side effects.Table 2Epigenetic modulators of CYP450.Table 2Epigenetic modulatorTargeted CYPTissue or cell lineEffect on CYPReferences**MiRNAs***Hsa-miR-25-3pCYP2B6*Human embryonic kidney (HEK) 293T cellsDownregulation[@bib31]*MiR-27bCYP1B1*Breast tumor and paired*-*normal tissueDownregulation[@bib91]*MiR-101 and miR-128-2CYP2D6*SH-SY5Y, and U251 cell linesDownregulation[@bib45]*Hsa-miR-370-3pCYP2D6*HepG2 cell lineDownregulation[@bib105]*MiR-142-3pCYP2D6*Mice bile acidUpregulation[@bib62]**LncRNAs***HNF1a-AS1CYP2C8, 2C9, 2C19, 2D6, 2E1, and 3A4*Human liver tissues and, Huh7 cellsUpregulation[@bib95]*Lnc-Ls*tr*CYP8b1*Plasma of miceUpregulation[@bib45]*Lnc-Hc*CYP7A1Rat hepatocyteDownregulation[@bib38]**DNA methylation and histone acetylation**Isoniazid*CYP1A1* and *CYP1B1*liver injury in ratDownregulation of *CYP1A1* and *CYP1B1*; Promotion of liver injury in rat[@bib46]Trichostatin A*CYP2E1*HepG2 cellsInduction of apoptosis and antitumor effects by acetylation of *CYP2E1* promoter[@bib100]IL-6*CYP1B1*CRC cell lines HCT116 and SW480Upregulation of *CYP1B1*;\
Promotion of colorectal cancer by increasing methylation of miR-27b promoter[@bib65]

6.1. Regulation by miRNA {#sec6.1}
------------------------

MiRNAs are a novel class of non-coding transcripts with 21--23 nucleotides length, and play a crucial role in a broad spectrum of disorders ([@bib88]; [@bib94])***.*** *In silico* and *in vitro* (human embryonic kidney (HEK) 293T cells) investigation on effect of hsa-miR-25--3p on expression levels of *CYP2B6* showed that hsa-miR-25--3p suppresses *CYP2B6* expression by binding to *CYP2B6* mRNA 3' UTR ([@bib31]). Furthermore, a study carried out on 24 patients with breast cancer (breast tumor and paired*-*normal tissue*)* showed a negative association between expression levels of miR-27b and *CYP1B1*. Also, it showed that *CYP1B1* contrary to miR-27b is highly expressed in cancerous tissues. CYP1B1 is expressed in estrogen-regulated tissues through catabolism of various procarcinogens, and 4-hydroxylation of 17β-estradiol ([@bib91]). Accumulating evidence showed that the expression levels of *CYP2D6* which have a fundamental role in HCQ metabolism is influenced by several miRNAs ([@bib62]; [@bib105]). Surprisingly, a study performed on SH-SY5Y, and U251 cell lines demonstrated that testosterone could decrease CYP2D6 activity by increasing the level of miR-101 and miR-128-2 which bind to the 3′ UTR of *CYP2D6* mRNA ([@bib45]). Investigation of HepG2 cell line transfection with hsa-miR-370--3p indicated that hsa-miR-370--3p decreases the expression of *CYP2D6* via binding to coding regions of the *CYP2D6* mRNA ([@bib105]). Astonishingly, examination of mice fed with cholic acid illustrated that it decreases the expression levels of small heterodimer partner (SHP) by targeting and inducing miR-142--3p. Decreasing of SHP, a transcriptional repressor of *CYP2D6* expression, induced by cholic acid is significantly associated with *CYP2D6* upregulation which emphasizes on the key role of bile acid levels in regulating *CYP2D6* expression ([Fig. 4](#fig4){ref-type="fig"} A) ([@bib62]).Fig. 4**Epigenetic mechanism influenced expression of *CYP2D6***.A: several miRNAs influence the expression levels of *CYP2D6* by binding to 3′ UTR and coding regions of *CYP2D6* mRNA; B: multiple lncRNAs including *HNF1a-AS1*, *lnc-LSTR*, and *lnc-HC* modulate several CYP enzymes by binding to *CYP* mRNAs; C: methylation and histone acetylation of *CYP* mRNAs promoter change the expression levels of multiple *CYPs*, and cause liver injury, apoptosis, and antitumor effects; SHP: small heterodimer partner; LPL: lipoprotein lipase; TG: triglyceride; APOC2: apolipoprotein C2; 5-aza-dC: 5-aza-2′-deoxycytidine; TSA: trichostatin A; ROS: reactive oxygen species; TLR: toll- like receptor; IL-6: interleukin 6; ERK: extracellular-signal-regulated kinase; TNF-α: tumor necrosis factor-α; *PPAR*-γ: peroxisome proliferator-activated receptor-γ.Fig. 4

6.2. Regulation by lncRNA {#sec6.2}
-------------------------

LncRNAs are other non-coding transcripts with longer than 200 nucleotides length, and have a pivotal role in promoting of wide spectrum disorders from cancer to neurodegenerative diseases. Recently, studies on human liver tissues and Huh7 cells demonstrated the positive correlation between expression levels of lncRNA hepatocyte nuclear factor 1 alpha antisense 1 (*HNF1a-AS1*), and several CYP enzymes including CYP2C8, 2C9, 2C19, 2D6, 2E1, and 3A4 ([@bib95]). The liver-specific triglyceride regulator (*lnc-Ls*tr) modulates the triglyceride plasma levels in mice by counteracting the repressor effects of TAR DNA binding protein 43 (TDP-43) on CYP8b1 promoter. *Lnc-Lstr* knocked-out mice led to repression of *Cyp8b1* and reduction in triglyceride plasma levels through inducing apolipoprotein C2 and lipoprotein lipase which are involved in triglyceride plasma clearance ([@bib45]). The high levels of cholesterol in rat induce the expression and binding of *Lnc-Hc*, a hepatocyte-specific lncRNA, to hnRNPA2B1. Lnc-HC/hnRNPA2B1 complex inhibits cholesterol-bile acid conversion by decreasing CYP7A1 ([Fig. 4](#fig4){ref-type="fig"}B) ([@bib38]).

6.3. DNA methylation and histone acetylation {#sec6.3}
--------------------------------------------

DNA methylation and histone acetylation are the important epigenetic modifications that cells use to control gene expression of large number of genes ([@bib92]; [@bib71]). In this view, *CYP* might be influenced by other epigenetic mechanisms such as DNA methylation, and histone modification ([@bib47], [@bib48]). Isoniazid induced promoter methylation of *CYP1A1* and *CYP1B1* resulted in their downregulation and liver injury promotion in rat. Indeed, liver injury occurs probably due to upregulation of *TLR4,* extracellular-signal-regulated kinase (*ERK*), peroxisome proliferator-activated receptor (*PPAR*)-γ, *IL-6*, and *TNF*-α*,* caused by decreasing levels of *CYP1A1* and *CYP1B1* ([@bib46]). Human hepatoma cell line HepG2 were treated with 5-aza-2′-deoxycytidine that inhibits DNA methylation, and trichostatin A that inhibits histone deacetylation caused expression changes in a wide spectrum of genes such as xenobiotic metabolism (*CYP3A4*, *CYP3A5*, and *CYP3A7*), and steroid biosynthesis (*CYP17A1* and *CYP19A1*) genes ([@bib18]). Trichostatin A is an antitumor drug that was shown to induce apoptosis in HepG2 cells through histone H3 acetylation of *CYP2E1* promoter. Trichostatin A-mediated *CYP2E1* upregulation promotes apoptosis and antitumor effects by producing mitochondrial reactive oxygen species ([Fig. 4](#fig4){ref-type="fig"}C) ([@bib100]). Astonishingly, the pro-inflammatory cytokine IL-6 that plays a fundamental role in promoting colorectal cancer, was shown to increase the expression levels of *CYP1B1 in vitro* and therefore mediates the metabolic activation of pro-carcinogens, which may lead to generation of reactive metabolites capable of damaging DNA by genome-wide methylation of miR-27b promoter ([@bib65]). It seems that epigenetic mechanisms including ncRNAs, DNA methylation, and histone modification might play a vital role in regulating the expression and function of CYP2D6 in metabolizing several drugs such as metoprolol, methotrexate, cyclosporine, H^+^/K^+^ ATPase pump inhibitors, CQ, and HCQ. However, further studies are required to investigate the possible connection between epigenetic-dependent changes in cytochrome P450 expression and actual changes in response to HCQ ([@bib37]; [@bib47], [@bib48]; [@bib83]).

7. Mechanism of retinopathy caused by hydroxychloroquine {#sec7}
========================================================

7.1. Mechanism underlying vision: role of RPE {#sec7.1}
---------------------------------------------

Light sensitivity is an essential process to intact vision ([@bib26]). Permanent sensitivity to light is provided by ongoing generation and condensation of rhodopsin on the photoreceptor outer segment discs by rough endoplasmic reticulum and Golgi apparatus ([@bib64]; [@bib75]). Photoreceptor inner segment supports the outer segment by supplying necessary substances. Also, the photoreceptor inner segment facilitates the elongation of photoreceptor outer segment toward RPE by continuous synthesis of discs ([@bib11]). A study conducted on retinal photoreceptors of multiple animal models including rhesus monkey, eastern gray squirrels, and California ground squirrels showed that photoreceptor outer segments are growing and extending continuously ([@bib79]). RPE cells protect photoreceptor outer segments via phagocytosis of the outer segment redundancies of photoreceptors ([@bib11]). RPE cells are playing a crucial role in maintenance of photoreceptors stability by transporting nutrients, electrolytes, ions, and water to the retina, and choroid capillaries. Deposition of debris in the extracellular space between RPE cells and photoreceptors were shown to be correlated with dystrophic retina. RPE cells prevent the accumulation of debris in photoreceptor outer segments by scavenging debris, and thereby causing rhodopsin cells renewal ([@bib34]). RPE cells transfection with mer tyrosine kinase (*MERTK*) siRNA resulted in phagocytosis inhibition, due to downregulation of *MERTK* which is involved in RPE phagocytosis activity ([@bib81]). Correspondingly, *Mertk* mutated Royal College of Surgeons rats were diagnosed with autosomal recessive retinitis pigmentosa which emphasized on the fundamental role of phagocytosis activity of RPE cells in visual intact function ([@bib21]).

7.2. Hydroxychloroquine promotes retinopathy by influencing lysosomes, phagocytes, and melanin {#sec7.2}
----------------------------------------------------------------------------------------------

The 4-aminoquinoline derivatives such as HCQ and CQ might cause retinopathy by affecting the lysosomal function, digestion ability of phagocytes, and binding to the melanin ([@bib9]; [@bib42]). HCQ and CQ enter the lysosome and inactivate its enzymes including N-acetyl-β-glucosaminidase, and cathepsin D through alteration of its vital acidic condition ([@bib89]). Moreover, HCQ and CQ cause massive aggregation of lysosomal associated organelles, membranous cytoplasmic bodies, and lipofuscin in RPE neuron cells by reducing the lysosomal acidic potency ([@bib52]). Ongoing accumulation of lipofuscin in the RPE cells induces a positive feedback resulting in more accumulation of lipofuscin. Progressive aggregation of lipofuscin gradually damages RPE cells, and may cause several diseases such as age-related macular degeneration, and Stargardt disease ([@bib20]; [@bib97]). In addition, lipofuscins aggregation in RPE cells may reduce the normal supportive function of RPE cells by disrupting organelle\'s cytoplasmic trafficking ([@bib69]; [@bib84]). Growing evidence suggest that HCQ promotes retinopathy by binding tightly to melanin in RPE. Furthermore, the strong binding of HCQ to melanin in other tissues including skin and ciliary bodies was shown to cause severe disorders such as skin hyperpigmentation ([Fig. 5](#fig5){ref-type="fig"} ) ([@bib19]; [@bib90]).Fig. 5**Mechanism of retinopathy caused by hydroxychloroquine**. Macula is a central part of retina which have vital role in central, high-resolution, and color vision. Retina is a thin layer near the optic nerve. Retina is containing ganglion cells, and photoreceptors which conduct visual transduction by converting light into nerve impulses. Hydroxychloroquine (HCQ) promotes retinopathy through inactivating lysosomal enzymes, blocking phagocytes\' digestion ability, binding to the melanin, and blocking organic anion transporter family member 1A2 OATP1A2. QATP1A2 is involved in visual cycle by transporting of all-trans-retinol (atROL) (vitamin A) from the interphotoreceptor matrix to the retinal pigment epithelia (RPE). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 5

7.3. Blocking of organic anion transporter family member 1A2 (OATP1A2) by hydroxychloroquine promotes retinopathy {#sec7.3}
-----------------------------------------------------------------------------------------------------------------

Visual cycle is a vital process to visual perception that is conducted by engaging transporters and binding proteins ([@bib86]). Visual cycle exchanges vitamin A compounds (retinol) and facilitates signal transduction via providing substrates to the photoreceptors ([@bib8]). Carrier organic anion transporter 1A2 (*SLCO1A2*) encodes OATP1A2 which participates in retinol circulation ([@bib33]). Increasing evidence suggest that OATPs have a fundamental role in the endogenous and exogenous substances influx into several organs including liver (OATP1B1), kidney, intestine, brain, and liver (OATP1A2) ([@bib104]). OATP1B1 is the most important transporter expressed in hepatocytes and is localized in the sinusoidal membrane of hepatocytes. OATP1A2 is located in RPE apex, and mediates the transport of all-trans-retinol (atROL) from the interphotoreceptor matrix to the RPE ([@bib10]). Interestingly, HCQ and CQ probably disrupt the activity of OATP1A2 in transporting of atROL influx by competing with atROL to occupation of OATP1A2. Consequently, atROL accumulates within the interphotoreceptor matrix, and results in deficiency of 11-cis-retinal (11cRAL) and rhodopsin, and thereby caused impaired vision ([@bib99]).

8. Discussion {#sec8}
=============

The current novel SARS-CoV-2 has been widely spread throughout the world (203 countries) with high mortality and morbidity ( [@bib98]). A global effort is underway to find a potential drug to counter SARS-CoV-2 ([@bib60]). Recently, growing body of evidence showed that HCQ might be a potential drug to counteract the novel coronavirus ([@bib27]; [@bib49], [@bib50]; [@bib101]). HCQ and CQ were administrated to patients affected with infectious diseases (HIV and influenza), and immune diseases (RA and SLE) ([@bib14]; [@bib61]; [@bib70]). Several investigations have reported that HCQ has a higher safety and anti-viral activity to combat COVID-19 in comparison with CQ ([@bib101]; [@bib49], [@bib50]). In this context, an *in vitro* study carried out on African green monkey kidney Vero cells infected by SARS-CoV-2 and treated with HCQ and CQ showed that both of them decreased the viral replication in a concentration-dependent manner although HCQ showed a larger *in vitro* antiviral effects relative to CQ ([@bib101]). An investigation conducted in Shanghai, China, on 30 confirmed cases with COVID-19 including 15 cases that were given conventional treatment and 15 cases that were given 400 mg per day HCQ along with conventional treatment for 5 days revealed the similar frequency of negative patients for nasopharyngeal swabs test of COVID-19 on day 7 after treatment between two groups. Also, the median time of normalization of body temperature was similar in both groups, whereas worsening computerized tomography findings of lung were seen in 5 patients (33.3%) of case group and 7 subjects (46.7%) of control group ([@bib12], [@bib13]). A clinical trial study performed on 36 French confirmed SARS-CoV-2 cases (6 patients left the study) including 20 cases that were given HCQ (600 mg/day) (6 of them received azithromycin (500 mg on day 1 followed by 250 mg/day, the next four days) along with HCQ), and 16 cases receiving neither HCQ nor azithromycin illustrated a positive effect of combination therapy on ameliorating clinical manifestations. Surprisingly, their findings demonstrated that the nasopharyngeal PCR test at days 6 after treatment was negative for 100% of cases that underwent combined therapy whereas only 57% of patients that received HCQ only, and 12.5% of control group patients showed a negative nasopharyngeal PCR test ([@bib27]). The discrepancy between results of Shanghai and French study may be due to small sample size in both study or combination of HCQ and azithromycin in the French study in comparison with Shanghai study which used conventional and HCQ treatment. Strikingly, the achieved results from study performed on 11 patients affected with SARS-CoV-2 (7 men and 4 women) that 8 had significant comorbidities associated with poor outcomes (obesity: 2; solid cancer: 3; hematological cancer: 2; HIV-infection: 1) have shown an inconsistent finding about co-administration of azithromycin and HCQ (the dosage was similar to French study) in comparison with French study. It was revealed that one patient died, two were transferred to the ICU, and therapy was discontinued in one patient due to prolongation of the QT interval. Also, PCR test from nasopharyngeal swabs of 10 patients who were alive showed a positive SARS-CoV-2 finding in 8 of them on day 5--6 post treatment ([@bib57]). Different response of patients affected with COVID-19 to HCQ supports the hypothesis that different *CYP* SNPs and epigenetic mechanisms might be responsible for different HCQ metabolism, and therefore different response. The CYP450 and its isoforms have a key role in metabolism and conversion of HCQ into pharmacologically active substances ([@bib80]). The effects of *CYP* SNPs on variable metabolism of HCQ and CQ among different individuals were investigated. Achieved results from a study conducted on 194 patients suffering from SLE that were given HCQ for more than 3 months showed the considerable effects of *CYP2D6* SNPs on blood HCQ levels. Patients with GG genotype for rs1065852 showed a higher ratio of \[DHCQ\]:\[HCQ\] (DHCQ: N-desethyl HCQ is a product of HCQ metabolism) relative to patients with AA genotype that showed a lowest \[DHCQ\]:\[HCQ\] ratio. Correspondingly, patients with CC genotype for rs1135840 presented a higher \[DHCQ\]:\[HCQ\] ratio in comparison with patients with GG genotype for rs1135840 ([@bib43]). Besides, several studies reported multiple drug-drug interactions for HCQ and other drugs including metoprolol, methotrexate, cyclosporine, and H^+^/K^+^ ATPase pump inhibitors (omeprazole, lansoprazole, pantoprazole, esomeprazole, and rabeprazole) ([@bib6]; [@bib39]; [@bib59]; [@bib77]). Also, there are some evidence about the critical role of ncRNAs, DNA methylation, and histone modification in *CYP* expression regulation. Evidence of miRNAs and lncRNAs\' role in regulating expression levels of *CYP* raise the possibility that other competing RNAs such as circular RNAs and pseudogenes may also play a crucial role in regulation of *CYP* expression. IL-6, is a proinflammatory cytokine that increases the expression levels of *CYP1B1* by epigenetic mechanisms, and thereby promotes colorectal cancer. Given the higher expression levels of *IL-6* in patients infected with SARS-CoV-2 in comparison with normal subjects, there is a possibility that IL-6 interferes with HCQ metabolism by affecting the expression of some nc-RNAs. Also, nc-RNAs could be a potential biomarker to prognosis, and diagnosis of pateints infected with SARS-CoV-2. Recent studies on nc-RNAs have shed some light on their potential role in therapeutic content. Beside the effectiveness of HCQ in counteracting SARS-CoV-2, there are some reports about the side effects of HCQ including cardiotoxicity, rhythm disorders (prolonged QT interval), gastrointestinal difficulties (dyspepsia, abdominal cramps, and dysgeusia), central nervous system disorders (headaches, dizziness, anxiety, and rarely psychosis and convulsions), skin disorders (rash and discoloration), and retinopathy ([@bib1]; [@bib32]; [@bib66]). Administration of higher dosage of HCQ in patients with SARS-CoV-2 raised the possibility that HCQ induced-side effects may probably take place more rapidly. On the other hand, studies showed that retinopathy induced by HCQ could progress and become irreversible even after drug cessation in some patients ([@bib63]; [@bib103]). Investigation on 218 RA patients under HCQ treatment via spectral domain optical coherence tomography, fundus autofluorescence, and visual fields demonstrated that 9 (4.1%) showed a toxicity. Eight out of 9 showed predominantly pericentral pattern of retinal change, and 1 showed the classic parafoveal distribution of retinal damage. Also, a significant progression of retinopathy was seen in 3 patients ([@bib42]). Achieved results from a retrospective study (2005--2009) on 85 patients suffering from RA that were given HCQ or CQ indicated that 21 (24.7%) out of 85 developed retinopathy. Also, they revealed that patients that underwent CQ treatment were significantly more susceptible to retinopathy in comparison with patients who underwent HCQ treatment (P = 0.001) ([@bib35]). Given the high morbidity and mortality rate from the current SARS-CoV-2 pandemy, global attempts are ongoing to find an effective drug to combat it. In recent weeks several clinical trials were conducted to clarify the effectiveness of HCQ in diminishing clinical manifestations of SARS-CoV-2 including body temperature, computerized tomography findings of the lung, viral load, and time of hospitalization. Administration of HCQ to manage patients infected with SARS-CoV-2 was challenged by several side effects especially retinopathy and different metabolism of HCQ among individuals with different *CYP450* genotypes. Given the achieved results from study conducted by [@bib42] we speculated that SNPs may explain partly the different response of subjects to the equal dosage of HCQ in Shanghai and French study. It\'s noteworthy to emphasize on regular ophthalmologic screening to check the HCQ mediated-retinopathy. Also, *CYP450* genotyping especially for *CYP2D6* may help to determine the best HCQ dosage in the context of personalized medicine.
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[^1]: HCQ: hydroxychloroquine; CQ: chloroquine.
